EDGE-TO-EDGE REPAIR (TEER)
Build upon clip-based platform, TriClip™ Transcatheter Edge-to-Edge-Repair (TEER) offers a minimaly invasive treatment option for patients with symptomatic, severe Tricuspid Regurgitation (TR) who are at high risk for surgery.
THE FIRST CHOICE TO RESTORE THE TRICUSPID VALVE1
TriClip TEER has shown meaningful outcomes in both real-world and randomized clinical data. bRIGHT and TRILUMINATE™ Pivotal Trials demonstrated the safety and effectiveness of TriClip TEER in the treatment of severe Tricuspid Regurgitation (TR).2-6
IMPROVING QUALITY OF LIFE WITHOUT COMPROMISE2
The TRILUMINATE™ Pivotal Trial demonstrated that TriClip TEER therapy was superior to medical therapy alone in improving quality of life and reducing Tricuspid Regurgitation.
TR Grade (Core Lab)
Freedom From
MAEs
New Pacemaker Implantation
Device Thrombus
Survival
Nonelective CV
Surgery from Device-Related AE
Device Embolization
71%
OF PATIENTS HAD MASSIVE
OR TORRENTIAL TR
4.4±0.7cm
TRICUSPID VALVE
ANNULUS DIAMETER
>35%
OF PATIENTS WITH PRIOR
VALVULAR INTERVENTION
15%
OF PATIENTS HAD A CRT, CRT-D, ICD,
OR PERMANENT PACEMAKER
TRILUMINATE PIVOTAL TRIAL DATA CARD
Get the latest data from the TRILUMINATE Pivotal Trial in a one-pager PDF format.
DISCOVER OUR LATEST CLINICAL OUTCOMES
bRIGHT
Real-world 1-Year Results of TriClip™ TEER from the bRIGHT Study
PROVEN ACROSS A BROAD RANGE OF ANATOMIES7,8
The bRIGHT Study demonstrated that TriClip™ TEER significantly reduced TR across a broad range of anatomies - in a safe and effective procedure - resulting in durable and meaningful clinical outcomes.
TR Grade (Core Lab)
NYHA Functional Class
KCCQ - OS
HIGH PROCEDURAL
SUCCESS
Implant sucess rate
SHORT
DEVICE TIME
78±41
Minutes
HIGH SAFETY
PROFILE
Freedom from MAEs
99.7%
SURVIVAL
1.3%
REINTERVENTION
0%
EMBOLIZATION
bRIGHT STUDY DATA CARD
Get the latest data from the bRIGHT Study in a one-pager PDF format.
PROVEN SAFETY AND EFFECTIVENESS
The TRILUMINATE™ Trial proved that TriClip TEER safely and effectively reduces TR and HF hospitalizations.
93%
SURVIVAL
AT 1 YR3
100%
IMPLANT
SUCCESS4
91%
ACUTE PROCEDURAL
SUCCESS RATE4
0%
STROKE4
0%
CONVERSION TO
SURGERY4
Durable reduction in tricuspid regurgitation (TR)
Durable improvements in NYHA
20 Points significant improvement in KCCQ-OS health-related quality of life at one-year
HIGH SURVIVAL IN A FRAGILE
PATIENT POPULATION
Survival
at 1 year
LOW RATES OF MAJOR
ADVERSE EVENTS
Freedom from MAEs
at 1 year
Reduced hospitalization rate
TRILUMINATE TRIAL DATA CARD
Get the latest data from the TRILUMINATE Trial in a one-pager PDF format.
Clinical Case clubs | Educational tools | Hot topics
Expert opinions | Live & online discussions
TV
T-TEER: Transcatheter Tricuspid Valve Repair - cases, tips, and tricks
T-TEER: echo procedural approach
T-TEER: patient selection and current evidence
Anatomical overview of the AV Valves
Screening Transmission | Mitral focus
TriClip - AVVS 1 year 1 minute Tricuspid - Video
MitraClip - AVVS 1 year 1 minute Mitral - Video
AV Valves Summit 2024 | Closing of Day 2
Trending Controversies | AV Valves
Case Parade | Mitral focus
- Data on file at Abbott.
- Sorajja P, Whisenant B, Hamid N, et al. TRILUMINATE Pivotal: A Landmark Randomized Clinical Trial of Transcatheter Tricuspid Valve Edge-to-Edge Repair For Tricuspid Regurgitation.” Presented at ACC; March 4, 2023; New Orleans, LA; USA.
- von Bardeleben RS, Lurz P, Sitges M, et al. Percutaneous edge-to-edge repair for tricuspid regurgitation: 2-year outcomes from the TRILUMINATE trial. Presented at: EuroPCR 2021.
- Lurz P, von Bardeleben RS, Weber M, et al. Transcatheter edge-to-edge repair for treatment of tricuspid regurgitation. J Am Coll Cardiol. 2021;77(3):229-239.
- Lurz P, Lapp H, Schueler R, et al. Real-world outcomes for tricuspid edge-to-edge repair: initial 30-day results from the TriClip™ bRIGHT Study. Presented at: EuroPCR; May 17-20, 2022; Paris, France.
- Nickenig G., Weber M., Lurz P., et al. Transcatheter edge-to-edge repair for reduction of tricuspid regurgitation: 6-month outcomes of the TRILUMINATE single-arm study. Lancet. 2019; 394 (10213): 2002-2011.
- Lurz P, Schmitz T, Bekeredjian R, et al. Real-world Outcomes for Tricuspid Edge-to-Edge Repair: Initial 1 Year Outcomes from the bRIGHT trial. Presented at PCR London Valves; November 27-29, 2022; London, England.
- Lurz P et al. Real-world Outcomes for Tricuspid Edge-to-Edge Repair: Initial 30-Day Results with TriClip™ G4 from the bRIGHT Study Presented at PCR London Valves 2022.